Announcements Trials
Browse Landscape

Phase

Phase 2 5

Status

Unknown 3Completed 1Active not recruiting 1

Sponsor Class

OTHER 4INDUSTRY 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 5Other solid neoplasm 5

Conditions

Carcinoma, Hepatocellular 37Carcinoma, Non-Small-Cell Lung 24Melanoma 19Squamous Cell Carcinoma of Head and Neck 18Colorectal Neoplasms 16Urinary Bladder Neoplasms 11Breast Neoplasms 11Lung Neoplasms 10Liver Neoplasms 10Biliary Tract Neoplasms 10Small Cell Lung Carcinoma 9Prostatic Neoplasms 9Diabetes Mellitus, Insulin-Dependent, 12 9Carcinoma, Renal Cell 9Neoplasms 8Cholangiocarcinoma 7Pancreatic Neoplasms 6Ovarian Neoplasms 6Head and Neck Neoplasms 6Adenocarcinoma Of Esophagus 6Stomach Neoplasms 5Neoplasm Metastasis 5Mesothelioma, Malignant 5Fallopian Tube Neoplasms 5Uterine Cervical Neoplasms 4Triple Negative Breast Neoplasms 3Recurrence 3Mesothelioma 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3

Interventions

Cisplatin 57Pemetrexed 46pembrolizumab 18Nivolumab 15Carboplatin 15Gemcitabine 14Cyclophosphamide 13Radiotherapy 10Drug Therapy 9atezolizumab 8Platinum 7Ipilimumab 7Doxorubicin 7durvalumab 61,2-diaminocyclohexaneplatinum II citrate 6tremelimumab 5sodium thiosulfate 5Vinorelbine 5Radiotherapy, Intensity-Modulated 5Interleukin-2 5Chemotherapy, Adjuvant 5Cerebral Decortication 5sargramostim 4fludarabine 4defactinib 4aldesleukin 4tumor necrosis factor-alpha, CNGRC fusion protein, human 3cediranib 3Photochemotherapy 3Neoadjuvant Therapy 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Mesothelioma, Malignant × tremelimumab × Clear all
NCT01843374 2026-03-05

Tremelimumab

MedImmune LLC

Phase 2 Active not recruiting
571 enrolled 19 charts
Other solid neoplasmThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Mesothelioma, Malignant

NCT05380713 2025-12-29

......SMARTEST Trial......

University Health Network, Toronto

Phase 2 Completed
30 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT02588131 2015-10-27

A Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Antibody in Malignant Mesothelioma (NIBIT-MESO-1)

Italian Network for Tumor Biotherapy Foundation

Phase 2 Unknown
40 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01655888 2012-08-02

The Anti-CTLA-4 Monoclonal Antibody Tremelimumab in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

NCT01649024 2012-07-25

A Clinical Study With Tremelimumab as Monotherapy in Malignant Mesothelioma

Azienda Ospedaliera Universitaria Senese

Phase 2 Unknown
29 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡